News & Events – Page 4 – Shanghai ChemPartner

ChemPartner’s New Scientific Center of Excellence!

We are delighted to announce the completion of Phase 1 of our new South San Francisco Labs. Please join us for a reception to celebrate this important new initiative for ChemPartner. Our CEO, Michael Hui will be hosting this event and will be delighted to share our vision for the future of partnership/ collaboration with ChemPartner and other members of the broader ShangPharma family. Wednesday, November 4th, 2015 4pm–7pm ChemPartner San Francisco 280 Utah Avenue | South San Francisco | CA 94080 RSVP to tsotto@chempartner.com

11/04/2015 | Press Release |

2015 Qidong Science and Technology Festival

ShangPharma Biopharmaceutical Innovation and Development Forum is going to begin on October 19th , 2015, at Qidong Evergrande International Conference Center. As one of the serial activities of 2015 Qidong Science and Technology Festival, this Forum is co-hosted by ShangPharma Group, Qidong Municipal Government, Shanghai Biopharmaceutics Industry Association and GE Healthcare China. ShangPharma Group is one of the leading CROs as well as a full-service research platform in Biopharmaceutical area. During this Forum, ShangPharma, together with research institutes, universities and biopharmaceutical industries, will discuss the latest trend in the area of biomedical sciences. Several well-known scholars, industrial top managers and technology elites are invited to give speeches about the frontier researches and new technologies of biological macromolecules and related disease areas. For more detailed information please refer to the invitation and schedule of the Forum below. You can also reach the organization committee by calling 86-21-51320006, or sending email to wjliu@shangpharma.com. Welcome to the ShangPharma Biopharmaceutical Innovation and Development Forum.

10/09/2015 | Press Release |

ChemPartner to showcase cutting edge researches at AACR

Multi-omics approach to elucidate mechanism of cancer drug resistance SHANGHAI – [Apr. 13th, 2015] – ChemPartner, a leading science driven, technology based, high quality preclinical research partner for healthcare companies around the world, will unveil its technological advancement to help answer basic and clinical research questions on cancer drug resistance, at the upcoming AACR Annual Meeting in Philadelphia, PA on April 18th- 22nd. ChemPartner scientists started with the more clinically relevant PDX models. Rather than using cell lines exposed to treatments in tissue culture to generate drug-resistance, an in vivo long term drug exposure was utilized to generate a drug insensitive version of the disease. Such resistance was generated in the context of tumor-host interaction, much closer to real patient situation. A primary tumor cell line was then generated from a tumor developed on long-term sorafenib treatment, as well as another cell line derived from PDX tumor without sofafenib treatment. Team at ChemPartner continued to perform microarray analyses and RT-qPCR verification, whole exome sequencing, RNA-seq, and metabolomic analyses on these two cell lines, followed by data analysis and integration by bioinformatics team. The findings from this multiple-omics approach will be presented at the AACR annual meeting in Philadelphia next week. ChemPartner Oncology has been providing services to over 150 global Pharmaceutical and Biotechnology companies since 2006. It is best known for its biggest cell panel (with over 700 cell lines) and most comprehensive assays for epigenetic enzyme (130+ epigenetic enzymes) along with extensive experience in cancer metabolism, epigenetics and tumor immunology research. In recent years, ChemPartner Oncology also established close collaborations with hospitals to expand translational research through an affiliate, Clinical Explorer. Patient-derived-xenograft models are among the fruitful results of such collaborations. Building on the deep and growing expertise in preclinical research and biomarker studies, Clinical Explorer strives to become...

04/14/2015 | Press Release |

ChemPartner Announces Opening of San Francisco Research Facility

New facility to help bring CRO to next level of scientific excellence SHANGHAI – [Feb. 3rd, 2015] – ChemPartner, a leading science driven, technology based, high quality preclinical research partner for healthcare companies around the world, recently expanded its global footprint with the establishment of a 24,000 square foot, state-of-the-art research facility in South San Francisco. ChemPartner is the service division of the ShangPharma group. “We are very excited to announce the opening of ChemPartner’s new state-of-the-art research facility in South San Francisco, one of the global centers of innovation in life science,” said ChemPartner founder and CEO Michael Hui. “In drug discovery, scientific excellence is the key to success,” Mr.Hui continued. “By taking the CRO service business to the next level, this new facility will help enable our customers, partners, and business collaborators to interrogate the most complex of drug discovery projects.” ChemPartner’s new research facility will be staffed by experienced drug research scientists from leading biotechnology companies who will collaborate closely with ChemPartner’s scientists based in China. “In addition to proximity to the top industry talent, the new facility brings ChemPartner services closer to the biopharmaceutical communities in the US, and will enable us to develop more innovative ways to bring value to our partners.” The Company noted that the new facility is the first step in a planned build-out of ChemPartner’s research presence in major innovation hubs around the world. About ChemPartner & ShanghPharma: The service division of the ShangPharma group, ChemPartner, is a leading research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. The company offers a broad range of high-quality, integrated services across the drug discovery and development process to pharmaceutical and biotechnology companies around the globe. ChemPartner’s services consist of discovery biologics, discovery chemistry, discovery biology and preclinical development, pharmaceutical...

02/04/2015 | Press Release |